Posted by Michael Wonder on 16 Jan 2020
Novavax granted fast track designation for NanoFlu in older adults
15 January 2020 - Novavax today announced that the U.S. FDA has granted fast track designation for NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate, adjuvanted with Matrix-M, in adults 65 years of age and older.
NanoFlu is a recombinant hemagglutinin protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system.
